News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,367 Results
Type
Article (40883)
Company Profile (267)
Press Release (680207)
Multimedia
Podcasts (80)
Webinars (17)
Section
Business (204656)
Career Advice (2022)
Deals (35532)
Drug Delivery (110)
Drug Development (81375)
Employer Resources (173)
FDA (16406)
Job Trends (14942)
News (346360)
Policy (32724)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2565)
Accelerated approval (31)
Adcomms (24)
Allergies (139)
Alliances (49575)
ALS (169)
Alzheimer's disease (1663)
Antibody-drug conjugate (ADC) (306)
Approvals (16670)
Artificial intelligence (507)
Autoimmune disease (150)
Automation (38)
Bankruptcy (361)
Best Places to Work (11637)
BIOSECURE Act (20)
Biosimilars (187)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (55)
Breast cancer (633)
Cancer (4767)
Cardiovascular disease (396)
Career advice (1707)
Career pathing (35)
CAR-T (279)
CDC (44)
Celiac Disease (2)
Cell therapy (736)
Cervical cancer (36)
Clinical research (69520)
Collaboration (1686)
Company closure (4)
Compensation (1148)
Complete response letters (53)
COVID-19 (2709)
CRISPR (87)
C-suite (826)
Cystic fibrosis (143)
Data (6179)
Decentralized trials (2)
Denatured (25)
Depression (131)
Diabetes (498)
Diagnostics (6681)
Digital health (46)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (250)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (228)
Earnings (90068)
Editorial (55)
Employer branding (21)
Employer resources (152)
Events (117221)
Executive appointments (965)
FDA (19498)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1454)
Gene editing (191)
Generative AI (43)
Gene therapy (589)
GLP-1 (964)
Government (4654)
Grass and pollen (6)
Guidances (383)
Healthcare (18870)
HIV (56)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (247)
Immuno-oncology (56)
Indications (105)
Infectious disease (2970)
Inflammatory bowel disease (187)
Inflation Reduction Act (14)
Influenza (112)
Intellectual property (244)
Interviews (315)
IPO (16640)
IRA (49)
Job creations (3641)
Job search strategy (1427)
JPM (56)
Kidney cancer (15)
Labor market (83)
Layoffs (545)
Leadership (30)
Legal (7948)
Liver cancer (91)
Longevity (14)
Lung cancer (644)
Lymphoma (374)
Machine learning (42)
Management (59)
Manufacturing (786)
MASH (161)
Medical device (13760)
Medtech (13813)
Mergers & acquisitions (19959)
Metabolic disorders (1259)
Multiple sclerosis (160)
NASH (16)
Neurodegenerative disease (312)
Neuropsychiatric disorders (86)
Neuroscience (2882)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4509)
Now hiring (65)
Obesity (591)
Opinion (257)
Ovarian cancer (165)
Pain (197)
Pancreatic cancer (222)
Parkinson's disease (279)
Partnered (33)
Patents (489)
Patient recruitment (478)
Peanut (55)
People (58832)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21672)
Phase 2 (30600)
Phase 3 (22794)
Pipeline (5171)
Policy (279)
Postmarket research (2564)
Preclinical (9193)
Press Release (64)
Prostate cancer (236)
Psychedelics (47)
Radiopharmaceuticals (278)
Rare diseases (824)
Real estate (5954)
Recruiting (70)
Regulatory (24443)
Reports (52)
Research institute (2385)
Resumes & cover letters (351)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (146)
Series A (237)
Series B (190)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3613)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (53)
Vaccines (991)
Venture capital (86)
Weight loss (378)
Women's health (89)
Worklife (18)
Date
Today (150)
Last 7 days (629)
Last 30 days (2195)
Last 365 days (29860)
2026 (3071)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55713)
2020 (54084)
2019 (46542)
2018 (35019)
2017 (32108)
2016 (31484)
2015 (37552)
2014 (31319)
2013 (26347)
2012 (28572)
2011 (29265)
2010 (27330)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (307)
Arkansas (13)
Asia (39201)
Australia (6406)
California (11203)
Canada (3264)
China (1091)
Colorado (474)
Connecticut (472)
Delaware (333)
Europe (84465)
Florida (1669)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (853)
India (64)
Indiana (516)
Iowa (22)
Japan (423)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1372)
Massachusetts (8032)
Michigan (320)
Minnesota (622)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2978)
New Mexico (28)
New York (2952)
North Carolina (1443)
North Dakota (8)
Northern California (5465)
Ohio (331)
Oklahoma (21)
Oregon (41)
Pennsylvania (2262)
Puerto Rico (23)
Rhode Island (47)
South America (1107)
South Carolina (65)
South Dakota (1)
Southern California (4360)
Tennessee (173)
Texas (1732)
United States (39719)
Utah (334)
Vermont (1)
Virginia (258)
Washington D.C. (81)
Washington State (915)
West Virginia (4)
Wisconsin (107)
Wyoming (2)
721,367 Results for "ansys inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Ansys Enables 3D Multiphysics Visualization of Next-Generation 3D-IC Designs with NVIDIA Omniverse
Ansys (NASDAQ: ANSS) today announced that it is adopting NVIDIA Omniverse application programming interfaces (APIs) to offer 3D-IC designers valuable insights from Ansys’ physics solver results through real-time visualization.
June 19, 2024
·
3 min read
Pharm Country
Ansys Chief Executive Officer to Present at the 49th Nasdaq Investor Conference
ANSYS, Inc. announced that Ajei Gopal, president and chief executive officer, will participate in a moderated discussion at the 49th Nasdaq Investor Conference, held in association with Morgan Stanley at the May Fair Hotel in London on Wednesday, December 6, 2023, at 8:30 a.m. ET or 1:30 p.m. GMT.
November 20, 2023
·
2 min read
Business
Ansys to Release Second Quarter 2023 Earnings on August 2, 2023
ANSYS, Inc. (NASDAQ: ANSS) announced today that the Company expects to release its second quarter earnings on Wednesday, August 2, 2023, after the market closes.
July 13, 2023
·
2 min read
Business
Ansys Expands Presence to Africa with New Office in Rwanda
Ansys, the global leader and innovator of engineering simulation software, is establishing its first physical presence in Africa with a new office in Kigali, Rwanda.
June 22, 2023
·
3 min read
Press Releases
BioSyent to Acquire Oral Science Inc.
February 9, 2026
·
10 min read
Pharm Country
Ansys Announces GlobalFoundries Certification of Semiconductor Tools for GF 22FDX® Platform
Ansys (NASDAQ: ANSS) today announced that GF has certified Ansys® RedHawk-SC™, Ansys® RaptorH™ and Ansys® HFSS™ semiconductor tools for its flagship 22FDX platform.
December 5, 2022
·
3 min read
Press Releases
Convatec awarded Enterostomal Therapy Products agreements with Premier, Inc.
February 10, 2026
·
2 min read
Press Releases
Repare Announces Completion of Acquisition by XenoTherapeutics, Inc.
January 29, 2026
·
6 min read
Press Releases
Encision Inc. Announces Fiscal 2026 Third Quarter Results
February 4, 2026
·
1 min read
Business
Ansys to Release Fourth Quarter and FY 2022 Earnings on February 22, 2023
ANSYS, Inc. (NASDAQ: ANSS) announced today that the Company expects to release its fourth quarter and FY 2022 earnings on Wednesday, February 22, 2023, after the market closes.
January 19, 2023
·
2 min read
1 of 72,137
Next
